Cost-of-illness in patients with moderate to severe psoriasis: A cross-sectional survey in Hungarian dermatological centres

Orsolya Balogh, Valentin Brodszky, László Gulácsi, Emese Herédi, Krisztina Herszényi, Hajnalka Jókai, Sarolta Kárpáti, Petra Baji, Éva Remenyik, Andrea Szegedi, Péter Holló

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Despite the widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies. Objectives: To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary. Methods: Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures. Results: Two-hundred patients were involved (females 32%) with a mean age of 51 (SD 13) years, 103 (52%) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was €9,254/patient/year (SD 8,502) with direct costs accounting for 86%. The main cost driver was BST (mean €7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy €2,186 (4,165), TST €2,388 (4,106) and BST €15,790 (6,016) (p < 0,001). Patients with BST had better PASI and DLQI scores (p < 0.01) than the other two subgroups. Conclusions: Patients with biological treatment have a significantly better quality of life and higher total costs than patients with or without traditional systemic treatment. Our study is the largest in Europe and the first in the CEE region that provides cost-of-illness data in psoriasis involving patients with BST.

Original languageEnglish
Pages (from-to)S101-S109
JournalEuropean Journal of Health Economics
Volume15
Issue numberSUPPL. 1
DOIs
Publication statusPublished - May 2014

Keywords

  • Biological treatments
  • Cost-of-illness
  • Psoriasis
  • Quality of life

ASJC Scopus subject areas

  • Economics, Econometrics and Finance (miscellaneous)
  • Health Policy

Fingerprint Dive into the research topics of 'Cost-of-illness in patients with moderate to severe psoriasis: A cross-sectional survey in Hungarian dermatological centres'. Together they form a unique fingerprint.

  • Cite this